Enanta Pharmaceuticals to Present Data for EDP-938, its Oral, Once-Daily, N-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2023
07 Setembro 2023 - 8:00AM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage
biotechnology company dedicated to creating novel, small molecule
drugs for viral infections, today announced that data for EDP-938,
its oral, once-daily, N-protein inhibitor in development for the
treatment of respiratory syncytial virus (RSV), will be presented
at IDWeek 2023 being held October 11 - 15, 2023 at the Boston
Convention and Exhibition Center in Boston, MA.
Date: Thursday, October 12, 2023 Time: 12:15 -
1:30 PM ET Abstract Number: 923 Poster Title:
“EDP-938, A Respiratory Syncytial Virus Antiviral, Demonstrates a
High Barrier to Resistance in a Human Challenge Study” Session
Title: Virology: Treatment and Prevention of Viral Infections
Location: Boston Convention and Exhibition Center Poster
Hall Presenter: Rachel Levene, Ph.D.
Further information about IDWeek 2023 can be found here.
About Enanta Pharmaceuticals, Inc. Enanta is using its
robust, chemistry-driven approach and drug discovery capabilities
to become a leader in the discovery and development of small
molecule drugs for the treatment of viral infections. Enanta’s
research and development programs include clinical candidates for
the following disease targets: respiratory syncytial virus (RSV),
SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also
conducting research on a single agent targeting both RSV and human
metapneumovirus (hMPV).
Glecaprevir, a protease inhibitor discovered by Enanta, is part
of one of the leading treatment regimens for curing chronic
hepatitis c virus infection and is sold by AbbVie in numerous
countries under the tradenames MAVYRET® (U.S.) and MAVIRET®.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230907333204/en/
Media and Investors Contact Jennifer Viera 617-744-3848
jviera@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024